Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease

We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed levodopa pro-drug, and carbidopa compared with levodopa and carbidopa to stabilize levodopa plasma concentration fluctuations in Japanese patients with Parkinson's disease. In an ope...

Full description

Bibliographic Details
Main Authors:	Masahiro Nomoto, Masahiro Nagai, Noriko Nishikawa, Rina Ando, Yoshifumi Kagamiishi, Koji Yano, Shigeto Saito, Atsushi Takeda
Format:	Article
Language:	English
Published:	Elsevier 2018-12-01
Series:	eNeurologicalSci
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405650218300315

Similar Items

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study
by: Fabrizio Stocchi, et al.
Published: (2015-01-01)

Membranous nephropathy associated with the use of levodopa-carbidopa combination
by: V Chaitanya, et al.
Published: (2015-01-01)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
by: Nirosen Vijiaratnam, et al.
Published: (2017-09-01)

Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism
by: ABHIJITH LALESH MERAJOTH, et al.
Published: (2016-05-01)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
by: Jason Margolesky, et al.
Published: (2018-01-01)

Improvement of Primary Writing Tremor in Parkinson's Disease with Carbidopa/Levodopa
by: James P. Battista, et al.
Published: (2015-10-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
by: Juan Miguel Pilar Bautista, et al.
Published: (2020-01-01)

Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease
by: Rina Ando, et al.
Published: (2018-04-01)

LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
by: Luminita Celia POPA, et al.
Published: (2020-06-01)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
by: Bigman DY, et al.
Published: (2018-04-01)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
by: Kye Won Park, et al.
Published: (2020-09-01)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
by: Hiroshi Kataoka, et al.
Published: (2020-01-01)

Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience
by: Johan Virhammar, et al.
Published: (2017-03-01)

LEVODOPA PLUS CARBIDOPA: IS IT EFFECTIVE IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY MANAGEMENT?
by: H GHANBARI, et al.
Published: (2000-03-01)

The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study
by: Baba, Y., et al.
Published: (2022)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa
by: Cindy Zadikoff, et al.
Published: (2020-01-01)

Optimizing levodopa therapy for Parkinson&rsquo;s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
by: David J Brooks
Published: (2008-03-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
by: Hauser RA, et al.
Published: (2018-03-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics
by: Benedicta Obenewaa Dankyi, MPhil, et al.
Published: (2020-01-01)

Attempted Suicide in a Parkinsonian Patient Treated with DBS of the VIM and High Dose Carbidopa-Levodopa
by: Ayotunde Ayobello, et al.
Published: (2019-01-01)

Levodopa/carbidopa and entacapone in the treatment of Parkinson&rsquo;s disease: efficacy, safety and patient preference
by: Thomas M&uuml;ller
Published: (2009-01-01)

Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
by: Skodda S
Published: (2014-05-01)

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
by: Maria José Catalán, et al.
Published: (2017-09-01)

Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease
by: P. Martínez-Martín, et al.
Published: (2014-04-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease
by: Akiko Nakatsuka, et al.
Published: (2006-01-01)

Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease
by: Hiroshi Nagayama, et al.
Published: (2015-09-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
by: Werner Poewe, et al.
Published: (2020-06-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
by: Yassine Noui, et al.
Published: (2021-09-01)

Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
by: Miho Murata, et al.
Published: (2018-02-01)

Large left posterior fossa meningioma presenting with quadriplegia in a woman with history of carbidopa-levodopa resistant parkinsonism
by: Antonio Jose Reyes, et al.
Published: (2019-03-01)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo&reg;)
by: Paolo Solla, et al.
Published: (2010-08-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)